{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T04:33:14Z","timestamp":1793075594917,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031949","name":"Guardant Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031949","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofliquidbiopsy.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Liquid Biopsy"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jlb.2026.100501","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T15:59:02Z","timestamp":1789747142000},"page":"100501","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Minimal residual disease combined with radiological tumor volume as a tool for identification of resected NSCLC patients at high risk of recurrence"],"prefix":"10.1016","volume":"14","author":[{"given":"Michela","family":"Verz\u00e8","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4808-0308","authenticated-orcid":false,"given":"Roberta","family":"Minari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Bordi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Bocchialini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianmarco","family":"Martines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Pluchino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"D'Agnelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Gnetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnese","family":"Cosenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Balestra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Ampollini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovica","family":"Leo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Milanese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Roberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarissa","family":"Gallani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Malapelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Tiseo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jlb.2026.100501_bib1","series-title":"Cancer statistics, 2025","author":"Siegel","year":"2025"},{"issue":"4","key":"10.1016\/j.jlb.2026.100501_bib2","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.jlb.2026.100501_bib3","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","article-title":"Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.jlb.2026.100501_bib4","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.jtho.2024.02.011","article-title":"The International Association for the Study of lung cancer lung cancer staging Project: proposals for revision of the TNM stage groups in the forthcoming (Ninth) edition of the TNM classification for lung cancer","volume":"19","author":"Rami-Porta","year":"2024","journal-title":"J Thorac Oncol"},{"issue":"11","key":"10.1016\/j.jlb.2026.100501_bib5","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.annonc.2025.08.003","article-title":"Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"36","author":"Committee","year":"2025","journal-title":"Ann Oncol"},{"issue":"25","key":"10.1016\/j.jlb.2026.100501_bib6","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1056\/NEJMoa043623","article-title":"Vinorelbine plus Cisplatin vs. observation in resected Non\u2013Small-Cell lung cancer","volume":"352","author":"Timothy","year":"2005","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jlb.2026.100501_bib7","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa031644","article-title":"Cisplatin-Based adjuvant chemotherapy in patients with completely resected Non\u2013Small-Cell lung cancer","volume":"350","year":"2004","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jlb.2026.100501_bib8","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jtho.2024.06.010","article-title":"Neoadjuvant and adjuvant treatments for early stage resectable NSCLC: consensus recommendations from the international association for the study of lung cancer","volume":"19","author":"Spicer","year":"2024","journal-title":"J Thorac Oncol"},{"issue":"9","key":"10.1016\/j.jlb.2026.100501_bib9","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S1470-2045(06)70804-X","article-title":"Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial","volume":"7","author":"Douillard","year":"2006","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.jlb.2026.100501_bib10","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1002\/cncr.28679","article-title":"Use and impact of adjuvant chemotherapy in patients with resected non-small cell lung cancer","volume":"120","author":"Williams","year":"2014","journal-title":"Cancer"},{"issue":"9722","key":"10.1016\/j.jlb.2026.100501_bib11","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(10)60059-1","article-title":"Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data","volume":"375","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jlb.2026.100501_bib12","doi-asserted-by":"crossref","DOI":"10.3747\/co.20.1178","article-title":"Factors associated with referral to medical oncology and subsequent use of adjuvant chemotherapy for non-small-cell lung cancer: a population-based Study","author":"Kankesan","year":"2013","journal-title":"Curr Oncol"},{"issue":"18","key":"10.1016\/j.jlb.2026.100501_bib13","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-Mutated Non\u2013small-cell lung cancer","volume":"383","author":"Yi-Long","year":"2020","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.jlb.2026.100501_bib14","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","article-title":"Alectinib in resected ALK-Positive Non\u2013Small-Cell lung cancer","volume":"390","author":"Yi-Long","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jlb.2026.100501_bib15","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.jtho.2018.05.030","article-title":"Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC","volume":"13","author":"Rolfo","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"9","key":"10.1016\/j.jlb.2026.100501_bib16","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nrclinonc.2017.14","article-title":"Integrating liquid biopsies into the management of cancer","volume":"14","author":"Siravegna","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.jlb.2026.100501_bib17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12943-022-01577-x","article-title":"Liquid biopsies to occult brain metastasis","volume":"21","author":"Rehman","year":"2022","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jlb.2026.100501_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112817","article-title":"Lymph node micrometastasis in non\u2013small cell lung cancer","volume":"149","author":"Sun","year":"2022","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"10.1016\/j.jlb.2026.100501_bib19","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/his.14831","article-title":"Systematic review and meta-analysis of the prognostic impact of lymph node micrometastasis and isolated tumour cells in patients with stage I\u2013IIIA non-small cell lung cancer","volume":"82","author":"H\u00fcy\u00fck","year":"2023","journal-title":"Histopathology"},{"issue":"6","key":"10.1016\/j.jlb.2026.100501_bib20","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202216505","article-title":"Comparison of tumor\u2010informed and tumor\u2010na\u00efve sequencing assays for ctDNA detection in breast cancer","volume":"15","author":"Santonja","year":"2023","journal-title":"EMBO Mol Med"},{"issue":"1","key":"10.1016\/j.jlb.2026.100501_bib21","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41571-024-00967-y","article-title":"Minimal residual disease as a target for liquid biopsy in patients with solid tumours","volume":"22","author":"Pantel","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.jlb.2026.100501_bib22","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41571-024-00985-w","article-title":"Circulating tumour DNA in early stage and locally advanced NSCLC: ready for clinical implementation?","volume":"22","author":"Normanno","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"20","key":"10.1016\/j.jlb.2026.100501_bib23","doi-asserted-by":"crossref","first-page":"5586","DOI":"10.1158\/1078-0432.CCR-21-0410","article-title":"Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer","volume":"27","author":"Parikh","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"19","key":"10.1016\/j.jlb.2026.100501_bib24","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.1158\/1078-0432.CCR-24-1651","article-title":"Colorectal cancer recurrence prediction using a tissue-free epigenomic minimal residual disease assay","volume":"30","author":"Nakamura","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jlb.2026.100501_bib25","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13045-022-01355-8","article-title":"Circulating tumor DNA integrating tissue clonality detects minimal residual disease in resectable non-small-cell lung cancer","volume":"15","author":"Wang","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.jlb.2026.100501_bib26","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41591-024-03216-y","article-title":"Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma","volume":"31","author":"Black","year":"2025","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.jlb.2026.100501_bib27","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1158\/2159-8290.CD-21-0634","article-title":"Detecting liquid remnants of solid tumors: circulating tumor DNA minimal residual disease","volume":"11","author":"Moding","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jlb.2026.100501_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108528","article-title":"ctDNA can detect minimal residual disease in curative treated non-small cell lung cancer patients using a tumor agnostic approach","volume":"203","author":"Rosenlund","year":"2025","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jlb.2026.100501_bib29","doi-asserted-by":"crossref","DOI":"10.21037\/tlcr-22-390","article-title":"Role of ctDNA for the detection of minimal residual disease in resected non-small cell lung cancer: a systematic review","author":"Verz\u00e8","year":"2022","journal-title":"Transl Lung Cancer Res"},{"issue":"10","key":"10.1016\/j.jlb.2026.100501_bib30","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1002\/cncr.35263","article-title":"Detection of circulating tumor DNA with ultradeep sequencing of plasma cell-free DNA for monitoring minimal residual disease and early detection of recurrence in early-stage lung cancer","volume":"130","author":"Tan","year":"2024","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.jlb.2026.100501_bib31","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.ccell.2023.08.010","article-title":"Individualized tumor-informed circulating tumor DNA analysis for postoperative monitoring of non-small cell lung cancer","volume":"41","author":"Chen","year":"2023","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.jlb.2026.100501_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004574","article-title":"Recurrence prediction using circulating tumor DNA in patients with early-stage non-small cell lung cancer after treatment with curative intent: a retrospective validation study","volume":"22","author":"Schuurbiers","year":"2025","journal-title":"PLoS Med"},{"issue":"5","key":"10.1016\/j.jlb.2026.100501_bib33","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.annonc.2022.02.007","article-title":"Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer","volume":"33","author":"Gale","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jlb.2026.100501_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2021.10.018","article-title":"2O IMpower010: biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC","volume":"32","author":"Zhou","year":"2021","journal-title":"Ann Oncol"},{"issue":"10308","key":"10.1016\/j.jlb.2026.100501_bib35","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.jlb.2026.100501_bib36","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative durvalumab for resectable Non\u2013Small-cell lung cancer","volume":"389","author":"V","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jlb.2026.100501_bib37","doi-asserted-by":"crossref","DOI":"10.62347\/IFRH7248","article-title":"Adjuvant osimertinib therapy guided by ctDNA-assessed MRD in resected EGFR-mutated stage IA-IIA non-small-cell lung cancer: a randomized clinical trial study protocol","author":"Wang","year":"2024","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.jlb.2026.100501_bib38","doi-asserted-by":"crossref","DOI":"10.1111\/1759-7714.15251","article-title":"Postoperative ctDNA in indicating the recurrence risk and monitoring the effect of adjuvant therapy in surgical non-small cell lung cancer","author":"Tian","year":"2024","journal-title":"Thorac Cancer"},{"issue":"1","key":"10.1016\/j.jlb.2026.100501_bib39","doi-asserted-by":"crossref","first-page":"6770","DOI":"10.1038\/s41467-021-27022-z","article-title":"Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC","volume":"12","author":"Qiu","year":"2021","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.jlb.2026.100501_bib40","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1158\/2159-8290.CD-21-1486","article-title":"Longitudinal undetectable molecular residual disease defines potentially cured population in localized non\u2013small cell lung cancer","volume":"12","author":"Zhang","year":"2022","journal-title":"Cancer Discov"},{"issue":"12","key":"10.1016\/j.jlb.2026.100501_bib41","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1158\/2159-8290.CD-17-0716","article-title":"Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling","volume":"7","author":"Chaudhuri","year":"2017","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.jlb.2026.100501_bib42","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/cncr.33985","article-title":"Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non\u2013small cell lung cancer","volume":"128","author":"Li","year":"2022","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.jlb.2026.100501_bib43","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.annonc.2023.11.008","article-title":"Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small-cell lung cancer","volume":"35","author":"Tran","year":"2024","journal-title":"Ann Oncol"}],"updated-by":[{"DOI":"10.1016\/j.jlb.2026.100687","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:00:00Z","timestamp":1792800000000}}],"container-title":["The Journal of Liquid Biopsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950195426000470?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950195426000470?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T04:01:24Z","timestamp":1793073684000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950195426000470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":43,"alternative-id":["S2950195426000470"],"URL":"https:\/\/doi.org\/10.1016\/j.jlb.2026.100501","relation":{},"ISSN":["2950-1954"],"issn-type":[{"value":"2950-1954","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Minimal residual disease combined with radiological tumor volume as a tool for identification of resected NSCLC patients at high risk of recurrence","name":"articletitle","label":"Article Title"},{"value":"The Journal of Liquid Biopsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jlb.2026.100501","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of The International Society of Liquid Biopsy.","name":"copyright","label":"Copyright"}],"article-number":"100501"}}